Primary Pericardial Mesothelioma (PPM) is an astonishingly rare form an aggressive malignancy which arises from the serosal cells of the pericardium. Protheragen offers comprehensive services for the development of diagnostics and therapeutics for Primary Pericardial Mesothelioma (PPM). Our expertise spans from early-stage research to advanced preclinical development, leveraging state-of-the-art technologies and scientific rigor.
Overview of Primary Pericardial Mesothelioma (PPM)
Primary Pericardial Mesothelioma (PPM) is a very unusual form of cancer which develops in the pericardium—the membrane surrounding the heart. This type of mesothelioma represents less than 1% of the total cases, and its rarity adds greatly to the diagnostic difficulties associated with it. PPM shows non-specific chest pain, dyspnea, and fatigue as symptoms, which greatly procrastinates the diagnosis. The pericardial involvement leads to highly aggressive tumors with invasion of the surrounding cardiac structures, the myocardium, and the great vessels. The disease is characterized by the formation of pericardial effusion, which may lead to cardiac tamponade, constrictive pericarditis, and heart failure. The diagnosis of PPM is often made too late, in conjunction with its elusive nature and poor prognosis. Death is often the only point of diagnosis.
Fig.1 Histopathological findings of primary pericardial mesothelioma (PPM). (Yan, Y.,
et al., 2022)
Diagnostics Development for Primary Pericardial Mesothelioma (PPM)
Imaging Techniques
Advanced imaging techniques are critical in the diagnosis and staging of PPM. CT and PET scans help in the detection of pericardial masses, effusions, and associated metastases. CT imaging illustrates the presence of pericardial thickening and nodules, and adjacent structural involvement, and PET scans identify hypermetabolic lesions. These imaging studies are pivotal to the further diagnostic workup and the subsequent management of the condition
Histopathology and Immunohistochemistry
The tissue samples collected via pericardiocentesis or surgical resection are analyzed for atypical features of mesothelioma, which may present as spindle-shaped or epithelioid cells. The diagnosis is confirmed using immunohistochemical markers such as cytokeratin AE1/AE3, calretinin, D2-40, and WT1, which also help in differentiating PPM from other pericardial tumors. The diagnosis of mesothelioma is further supported by the negative stain of TTF1 and claudin-4.
Genomic Sequencing
NGS has the capacity to determine the existence of mutations, alterations in the number of genes, and rearrangements in the genes of the tumors, as well as provide current information on the genetic structure of the disease. Tumor suppressor genes are inhibited in PPM in a recurring manner, including (CDKN2A/p16, CDKN2B, MTAP, BAP1, NF2, and TP53), which represent possible targets for therapeutics.
Therapeutics Development for Primary Pericardial Mesothelioma (PPM)
- Chemotherapy
Systemic chemotherapy is a critical component in the therapeutic plan for PPM, and usually involves cisplatin or carboplatin in combination with pemetrexed. This combination is effective in the therapeutics of pleural mesothelioma, and thus, is presumed to benefit patients with PPM. Chemotherapy is administered for the reduction of tumor burden, symptom relief, and survival prolongation. However, the rate of response is unpredictable, and reversal of the initial response is common.
- Targeted Therapies
Targeted therapy guided by genomics changes discovered via NGS technology is a new field of study in PPM. For example, PARP inhibitors have demonstrated efficacy in treating tumors with BRCA1/2 mutations, and such approaches might be applicable in the therapeutics of PPM with BRCA1 mutations. Other therapies aimed at the PI3K/AKT/mTOR pathway and MEK inhibitors are also being studied and could potentially address specific molecular changes contributing to the neoplastic growth.
Table 1. Therapeutics of primary pericardial mesothelioma (PPM).
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Chemotherapy |
Platinum-based (Cisplatin) |
DNA cross-linking to inhibit DNA replication and transcription |
A common chemotherapy drug used in combination to treat mesothelioma by interfering with tumor cell DNA repair. |
Approved |
| Chemotherapy |
Pemetrexed |
Inhibits folate-dependent enzymes to prevent DNA synthesis |
Used in combination with cisplatin, it disrupts tumor cell DNA synthesis, leading to cell death. |
Approved |
| Immunotherapy |
Ipilimumab |
Inhibits CTLA-4, enhancing T-cell activation against cancer cells |
Enhances the immune system's ability to attack tumor cells by blocking the CTLA-4 immune checkpoint. |
Preclinical |
| Immunotherapy |
Nivolumab |
PD-1 checkpoint inhibitor boosts immune response against cancer cells |
Another immune checkpoint inhibitor that helps T-cells attack mesothelioma cells more effectively. |
Preclinical |
| Adjuvant Therapy |
Bevacizumab |
Inhibits VEGF, preventing the formation of new blood vessels in tumors |
Used alongside chemotherapy to prevent the growth of blood vessels that supply the tumor. |
Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen is dedicated to advancing the field of PPM diagnostics and therapeutics through comprehensive and innovative services. We offer a wide range of services, including histopathological analysis, immunohistochemical staining, next-generation sequencing, and preclinical testing.
Disease Models
- Two-Dimensional (2D) Cell Lines
- Three-Dimensional (3D) Spheroids
- Organoid Models
- Patient-Derived Xenograft (PDX) Models
- Genetically Engineered Mouse Models (GEMMs)
Recognizing the unique challenges posed by PPM, Protheragen provides tailored solutions to meet the specific needs of our clients. Whether it's the development of a novel diagnostic assay or the optimization of a therapeutic candidate, our team works closely with clients to design and execute studies that address their research objectives. If you are interested in our services, please feel free to contact us.
References
- Yan, Yan, et al. "Primary malignant pericardial mesothelioma with a survival of 2.5 years: a case report." Translational Cancer Research 11.5 (2022): 1451.
- Seal, Steffan, Henry Simon, and Steffan T. Seal. "Primary pericardial mesothelioma: a rare but serious consideration." Cureus 13.11 (2021).
- Offin, Michael, et al. "Multimodality therapy in patients with primary pericardial mesothelioma." Journal of Thoracic Oncology 17.12 (2022): 1428-1432.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
